COVID-19

  • Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding
  • Applicant/Recipient COVID-19 Update History
  • CDC COVID-19
  • Get the latest research information from NIH | Español
Expand for resources

n/a Warning! This browser is not supported - Some features might not work. Try using a different browser such as Chrome, Edge, Firefox, or Safari.

  • U.S. Department of Health & Human Services
  • National Institutes of Health
Grants Home
  • eRA  |  new windowwNIH Staff   |  Glossary  |  FAQs  |  Help
  • Home
  • About Grants
    • Grants Process Overview
    • Get Started

    • Learn the Basics
    • Plan Your Application
    • How to Apply

    • Prepare to Apply
    • Write Application
    • Submit
    • How to Apply Video Tutorials

      Application Referral and Review

    • Receipt and Referral
    • Peer Review
    • Pre-Award and Post-Award Processes

    • Pre-Award and Award Process
    • Post Award Monitoring and Reporting
    • Forms Library

      Information For

    • Researchers
    • Research Administrators
    • Reviewers
    • Small Businesses Link to External Site
    • Foreign Grants
    • Media and the Public
    • NIH Staff Lock Icon
  • Funding
    • Find Grant Funding (NIH Guide to Grants and Contracts)
    • Other Transactions
    • Contracts
    • Research Training and Career Development Link to External Site
    • Loan Repayment Programs Link to External Site
    • Extramural Diversity Link to External Site
    • NIH Funding Strategies




      Notice IconAvoid Grant Scams
  • Policy & Compliance
    • NIH Grants Policy Statement
    • Notices of Policy Changes
    • Compliance & Oversight
    • Policy Topics

    • Animal Welfare Link to External Site
    • Application Submission Policies
    • Clinical Trial Requirements
    • Coronavirus Disease 2019 (COVID-19)
    • Early Stage Investigator Policies
    • Family-Friendly Initiatives
    • Financial Conflict of Interest
    • Human Subjects Research
    • Inclusion Policies
    • Intellectual Property Policy
    • Lobbying Guidance for Grantee Activities
    • Natural Disasters
    • NIH Funding Strategies
    • Peer Review Policies and Practices
    • Protecting U.S. Biomedical Intellectual Innovation
    • Public Access Link to External Site
    • Research Integrity
    • Rigor and Reproducibility
    • Sharing Policies Link to External Site
    • Supporting a Safe and Respectful Workplace
  • News & Events

      Latest News

    • News Highlights
    • "Open Mike" Blog Link to External Site
    • Extramural Nexus Link to External Site
    • Subscribe and Follow

    • Listservs
    • Social Media

      Virtual Learning

    • Webinars
    • Podcasts
    • NIH Grants YouTube Channel Link to External Site

      Connect In Person

    • NIH Regional Seminars on Program
      Funding & Grants Administration
    • SBIR-STTR Engage & Connect Link to External Site
    • Loan Repayment Program (LRP)
      Contact & Engage
       Link to External Site
    • Office of Laboratory Animal Welfare (OLAW)
      Workshops and Conference
      Link to External Site
    • Events Calendar
  • About OER
    • About the Office of Extramural Research
    • OER Offices

    • Immediate Office of the Director (IMOD)
    • Office of Policy for Extramural Research Administration (OPERA)
    • Office of Research Reporting and Analysis (ORRA)
    • Office of Laboratory Animal Welfare (OLAW)
    • Strategic Management and Contracts Office (SMCO)
    • Office of Electronic Research Administration (eRA)
    • Division of Communication & Outreach (DCO)
    • Small Business Education and Entrepreneurial Development (SEED)
    • Division of Biomedical Research Workforce (DBRW)
    • Division of Human Subjects Research (DHSR)
  • eRA
    Link to External Site
  • NIH Staff Lock Icon
  • Home
  • FAQs
  • Help

Policy & Compliance

  • NIH Grants Policy Statement
  • Notices of Policy Changes
  • Compliance & Oversight
  • Select Policy Topics+
    • Animal Welfare
    • Application Submission Policies
    • Clinical Trial Requirements+
      • Clinical Trial Definition
      • Why the Changes
      • Good Clinical Practice
      • Specific Funding Opportunities
      • New Form
      • Single IRB Policy
      • Protocol Template
      • Registration and Reporting
    • NIH Funding Strategies
    • Human Subjects Research
    • Intellectual Property Policy
    • Lobbying Guidance for Grantee Activities
    • Early Stage and Early Established Investigator Policies
    • Peer Review Policies and Practices
    • Public Access
    • Research Integrity
    • Anti-Sexual Harassment
    • Sharing Policies
Home  »   Policy & Compliance   »  Office of Laboratory Animal Welfare   »  Subject: Sources of Custom Antibody Production
Office of Laboratory Animal Welfare
OPRR REPORTS

Number 95-02

Animal Welfare


The Animal Welfare Division of OPRR was renamed Office of Laboratory Animal Welfare (OLAW) in 2000.

March 8, 1995

Subject: Sources of Custom Antibody Production

Dear Colleague:

This letter is being forwarded to Institutional Officials and Institutional Animal Care and Use Committee (IACUC) Chairs throughout the country. It is provided as guidance when determining sources for the production of antibodies in animals as part of activities supported by the Public Health Service (PHS), either directly or as a consequence of subgranting or subcontracting such production.

The Office for Protection from Research Risks (OPRR) is aware that some applicant organizations are uncertain about the PHS animal welfare requirements when animal use takes place outside the institution through subgrants or subcontracts. A common example of this is the production of antibodies using antigens provided by an investigator ("custom" antibodies) in animals. Institutions and investigators should be aware that if animals are utilized to produce such antibodies for use in PHS­supported research, the organization producing those antibodies must either have on file with OPRR an approved Animal Welfare Assurance (Assurance) or be included as a component of the applicant organization's Assurance. In addition, if species covered by the Animal Welfare Act are utilized, the producer must be registered as a "Research Facility" with the U.S. Department of Agriculture (USDA).

OPRR recognizes that many institutions have found it difficult to ensure that investigators procuring "custom" antibodies do so only from Assured sources. To facilitate and assist institutions in complying with PHS Policy requirements, OPRR urges PHS­supported investigators and institutions that utilize custom antibodies to follow the guidelines presented below.

When procuring custom antibody production services from non­institutional sources:

1) Contact the proposed producer to determine its Assured status, and if Assured, obtain the Assurance number. Alternatively, consult with OPRR for information on the Assured status of the preferred antibody producer. If the producer is Assured, the procurement action may proceed without additional actions. [NOTE: In cases where the intended producer is known at the time a grant proposal is being submitted to the National Institutes of Health, the producer's organization should be included as a performance site on the grant application.]

2) If the producer is not Assured, at least two options are available:

  • (a) Antibodies may be procured from other producers that are Assured; or

  • (b) The producer or the applicant organization may request that OPRR negotiate an Assurance with the producer's organization. [NOTE: If the producer was identified as a performance site on the grant application, the PHS funding component will notify OPRR of the need for an Assurance.] Upon successful completion of negotiations with the proposed producer and approval of an Assurance, which usually can be accomplished expeditiously, antibodies may be procured in accord with 1) above.

Adherence to the above guidelines will serve several worthwhile ends: (1) Animals involved in custom antibody production will be maintained and used in accord with federal humane standards; (2) antibody production will be conducted in a manner that is scientifically reliable; and (3) compliance burdens to investigators and institutions will be minimized.

/s/ /s/
Nelson L. Garnett, D.V.M.
Director, Division of Animal Welfare
Office for Protection from Research Risks
Gary B. Ellis, Ph.D.
Director
Office for Protection from Research Risks


Director, Office of Laboratory Animal Welfare
Office of Extramural Research,
Office of the Director, National Institutes of Health
RKL 1, Suite 360
6705 Rockledge Dr.
Bethesda, MD 20892-7982
(For express or hand-delivered mail use zip code 20817)
Telephone (301) 496-7163
olaw@od.nih.gov


This page last updated on May 12, 2004 
Content Manager: olaw@od.nih.gov 
Technical Issues: E-mail OER Webmaster   

Back to Top
  • Contact Us
  • Bookmark & Share
  • E-mail Updates
  • RSS Feed
  • Podcast
  • Twitter
  • YouTube

  • Search
  • Help Downloading Files
  • Disclaimer
  • Older Versions of this Page
  • Privacy Notice
  • Accessibility
  • HHS Vulnerability Disclosure
  • FOIA
  • U.S. Department of Health and Human Services
  • Grants.gov
  • USA.gov - Government Made Easy


  • National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

  • NIH... Turning Discovery Into Health